Arab Finance: Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) generated net income of EGP 204 million in the first half (H1) of 2026, 10% year-on-year (YoY) higher than  EGP 185 million in H1 2025, according to the emailed press release.

Revenues hiked by 16% YoY to EGP 2.121 billion in the January-June 2026 period from EGP 1.828 billion.

In the second quarter (Q2) of 2026, net profits increased by 1.7% to EGP 101 million from EGP 99 million in Q2 2025, while revenues climbed by 9.4% to EGP 1.054 billion from EGP 963 million.  

Performance was led by domestic tenders, which surged 68% YoY to EGP 92 million, driven by a 90% increase in tender volumes, while private sales grew 5.3% YoY to EGP 819 million.

Exports also increased 36% YoY to EGP 71 million, supported by a 22% increase in export volumes.

Amr Morsy, CEO of Rameda, commented: “We saw genuine breadth across our commercial channels, with demand remaining robust, exports continuing their recovery, and our private-market portfolio delivering another period of resilient performance.”

“Iraq returned as our largest export market, giving us renewed access to a channel that had been constrained through 2024 and early 2025, while contributions from Libya and Yemen, alongside new market entries in Jordan, Afghanistan, and Somalia, moved us meaningfully forward on our commitment to geographic diversification,” Morsy added.

He noted: “In tenders, sustained procurement activity by the Unified Procurement Authority translated into strong volume and value growth, with continued discipline in participating only where the profitability profile fits our strategy.”